Literature DB >> 28710658

Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Albert J Czaja1.   

Abstract

Autoimmune hepatitis has a variable occurrence, clinical phenotype, and outcome, and the factors contributing to this variability are uncertain. The goals of this review are to examine the global disparities in the occurrence and outcome of autoimmune hepatitis, suggest bases for these disparities, and encourage investigations that extend beyond single-center experiences. Disparities in the incidence and prevalence of autoimmune hepatitis in different age groups, genders, ethnicities, and geographical regions suggest that factors other than genetic predisposition are involved. Age- and gender-related antigen exposures from the external (infections, toxins, and medications) and internal (intestinal microbiome) environment may affect the incidence of the disease, and the timeliness and nature of treatment may influence its prevalence. The increasing incidence of autoimmune hepatitis in Spain, Denmark, and the Netherlands suggests that a new etiological trigger has been introduced or that the susceptible population has changed. Variations in mortality between Western and Asian-Pacific countries may result from differences in disease detection or management, and variations in gender predilection, peak age of onset, frequency of concurrent immune diseases, and serological profile may reflect gender-biased and age-related antigen exposures and genetic predispositions. Global collaborations, population-based epidemiological studies that identify case clustering, and controlled interview-based surveys are mechanisms by which to understand these disparities and improve management. In conclusion, autoimmune hepatitis has a rising incidence in some countries and variable occurrence, phenotype, and outcome between countries and subgroups within countries. These disparities suggest that unrecognized population-based environmental, infectious, or socioeconomic factors are affecting its character.

Entities:  

Keywords:  Autoimmune hepatitis; Epidemiology; Incidence; Mortality; Prevalence

Mesh:

Year:  2017        PMID: 28710658     DOI: 10.1007/s10620-017-4675-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  192 in total

1.  A gender gap in autoimmunity.

Authors:  C C Whitacre; S C Reingold; P A O'Looney
Journal:  Science       Date:  1999-02-26       Impact factor: 47.728

2.  Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.

Authors:  Yun Ma; Manabu Okamoto; Mark G Thomas; Dimitrios P Bogdanos; Agnel R Lopes; Bernard Portmann; James Underhill; Ralf Dürr; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

3.  Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity.

Authors:  N C Lambert; P C Evans; T L Hashizumi; S Maloney; T Gooley; D E Furst; J L Nelson
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

4.  Commensal microbiota influence systemic autoimmune responses.

Authors:  Jens T Van Praet; Erin Donovan; Inge Vanassche; Michael B Drennan; Fien Windels; Amélie Dendooven; Liesbeth Allais; Claude A Cuvelier; Fons van de Loo; Paula S Norris; Andrey A Kruglov; Sergei A Nedospasov; Sylvie Rabot; Raul Tito; Jeroen Raes; Valerie Gaboriau-Routhiau; Nadine Cerf-Bensussan; Tom Van de Wiele; Gérard Eberl; Carl F Ware; Dirk Elewaut
Journal:  EMBO J       Date:  2015-01-19       Impact factor: 11.598

5.  Reciprocal change with age in antibody to extrinsic and intrinsic antigens.

Authors:  M J Rowley; H Buchanan; I R Mackay
Journal:  Lancet       Date:  1968-07-06       Impact factor: 79.321

6.  Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

Authors:  Janet G M Markle; Daniel N Frank; Steven Mortin-Toth; Charles E Robertson; Leah M Feazel; Ulrike Rolle-Kampczyk; Martin von Bergen; Kathy D McCoy; Andrew J Macpherson; Jayne S Danska
Journal:  Science       Date:  2013-01-17       Impact factor: 47.728

7.  Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis.

Authors:  A J Czaja; M P Manns; H A Homburger
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

8.  Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis.

Authors:  Monica Miozzo; Carlo Selmi; Barbara Gentilin; Francesca R Grati; Silvia Sirchia; Sabine Oertelt; Massimo Zuin; M Eric Gershwin; Mauro Podda; Pietro Invernizzi
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

9.  Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population.

Authors:  P De Paoli; S Battistin; G F Santini
Journal:  Clin Immunol Immunopathol       Date:  1988-09

Review 10.  Autoimmune hepatitis in diverse ethnic populations and geographical regions.

Authors:  Albert J Czaja
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-05       Impact factor: 3.869

View more
  17 in total

Review 1.  Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination.

Authors:  Albert J Czaja
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

2.  Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis.

Authors:  Tugrul Purnak; Cumali Efe; Taylan Kav; Staffan Wahlin; Ersan Ozaslan
Journal:  Dig Dis Sci       Date:  2017-09-04       Impact factor: 3.199

3.  Missing Causality and Heritability of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2022-10-19       Impact factor: 3.487

Review 4.  Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis.

Authors:  Albert J Czaja; Aldo J Montano-Loza
Journal:  Dig Dis Sci       Date:  2018-10-28       Impact factor: 3.199

5.  Validating a novel algorithm to identify patients with autoimmune hepatitis in an administrative database.

Authors:  Therese Bittermann; Nadim Mahmud; James D Lewis; Cynthia Levy; David S Goldberg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-05-21       Impact factor: 2.732

6.  Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group.

Authors:  Nwe Ni Than; James Hodson; Daniel Schmidt-Martin; Richard Taubert; Rebecca E Wawman; Meemee Botter; Nishant Gautam; Kilian Bock; Rebecca Jones; Gautham D Appanna; Andrew Godkin; Aldo J Montano-Loza; Frank Lammert; Christoph Schramm; Michael P Manns; Mark Swain; Kelly W Burak; David H Adams; Gideon M Hirschfield; Ye Htun Oo
Journal:  JHEP Rep       Date:  2019-11-05

Review 7.  Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2019-12-07       Impact factor: 5.742

Review 8.  Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies.

Authors:  Elisabeth Sucher; Robert Sucher; Tanja Gradistanac; Gerald Brandacher; Stefan Schneeberger; Thomas Berg
Journal:  J Immunol Res       Date:  2019-11-25       Impact factor: 4.818

9.  Plasma proteomic analysis of autoimmune hepatitis in an improved AIH mouse model.

Authors:  Han Wang; Wei Yan; Zuohua Feng; Yuan Gao; Liu Zhang; Xinxia Feng; Dean Tian
Journal:  J Transl Med       Date:  2020-01-06       Impact factor: 5.531

10.  Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1.

Authors:  Maaike Biewenga; Xavier P D M J Verhelst; Martine A M C Baven-Pronk; Hein Putter; Aad P van den Berg; Karin C M J van Nieuwkerk; Henk R van Buuren; Gerd Bouma; Ynte S de Boer; Cedric Simoen; Isabelle Colle; Jeoffrey Schouten; Filip Sermon; Christophe van Steenkiste; Hans van Vlierberghe; Adriaan J van der Meer; Frederik Nevens; Bart van Hoek
Journal:  United European Gastroenterol J       Date:  2021-06-24       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.